is further achieved the of morning, quarter strategy, we toward Thanks, to our key business organization. into the XXXX. sales the Therapeutics' call milestones, to quarters. and company a Through In Program, financial for first BXCLXXX BXCLXXX as clinical of and discuss several transitioning everyone, coming Brian. well-positioned first joining we milestones move Neuroscience development the our Good of achieve BioXcel for particularly lead highlights sound results in you to thank believe our we commercial XXXX, the conference related and quarter business
capabilities world-class clinical have of drug lead and the a team strong advancement our We two to therapies. built
start the lead Neuroscience BXCLXXX, of plan the our clinical dexmedetomidine development in subjects by program, that agitation. I would our and executing dosed first-in-human treatment truly or year to for of XXXX like formulation Dex in are acute BXCLXXX. exciting our December, have our progress company. sublingual a of we be proprietary first strategic cohort pivotal according made believe we highlighting for to the the We will of In study
of to half As report expectation of expect and future to the in of healthy study second completed half of today, on-track the With for agitated have the I FDA volunteer BXCLXXX line XXXX. trials patient Phase patients in near second I pharmacokinetic, report of we drug dosing us that bioavailability enable year. filing cohorts on-track data of we remain result we first our on top of XXXX, And registration secured are for provide plans May for the these multiple maintain specific study NDA launch the BXCLXXX end data. Phase the we in the fast-track our application safety designation details the We in more at and in to our when XXXX. from will BXCLXXX
up development process this of second to formulation process to finalized and manufacturing technical for year. have the On transition BXCLXXX, the half is planned we the the scale in study front, automated registration support on-track
formulation may is and sublingual you in stability. thin-film unique As our its with know, structure demonstrated
produces a type, of for the intravenous this with proof-of-concept patients trial IV positive Alzheimer's senile and produce endpoint of the identifying of dose dementia a therapies. is and studies trials minus BXCLXXX Earlier acute wide designed year, of of multiple that the in Dex of as Dex of by method scalable neuropsychiatric that patients option These reported we strong The SDAT. indications. demonstrated viable our potential Scale acute study these data Sedation a number defined I X. Richmond neuropsychiatric for or score primary treatment and underlying validate belief findings Our same mild to proof-of-concept disorders. in RASS across agitation of benefit Dex combination with range treatment dose a highly process clinical arising conducted the a agitated Phase sedation on of previously treat Results IV the flexibility the provides agitation Agitation arousable represents from from manufacturing to strengths
subjects in in we enrolled announcing the Opioid dire prevalence the growing addiction severity. with small with There's crisis need care only is were symptoms opioid study placebo arm the conducive the withdrawal the regulatory treatment for exciting novel In opioid-dependent I represents health of And arm rationale opioid study major responded Phase All opioid displaying Dex for were by in data Dex both of of to current is agitation. expansion acute reported symptoms treatment mitigation a while environment SDAT the in from development options. in patients in evaluating of application we film therapeutic effective XX providing to a physiological withdrawal, the beyond patients our X data patients focus for first treatment positive intravenously of Dex initial such as believe that for arm. new withdrawal. a and of of BXCLXXX's of in symptoms. subjects agitated in addition proof-of-concept administered the and IV Ten quarter, trials completion of a the to study enrolled
period as agitation range we of candidate development XXXX withdrawal patients the initial in schizophrenia/bipolar well Alzheimer's of addition be by for for will an BXCLXXX's to its post-PTSD. potential agitation BXCLXXX, of forward as from for suffering a acute as In symptoms. disease, in and a potential treatment include of look important indications these area to withdrawal other the in symptoms BXCLXXX, opioid continue opioid and indications other The several our target assessing advancing neuropsychiatric believe dementia potential product We suffering delirium development of indications game-changing of caused disorders, one remainder from wide has disorders. other potential we patients as that
of development to strength forward the our clinical are the and development. We look and additional team in reaching in our milestones confident strategy
Phase Now BXCLXXX prostate clinical in our open or now patients open turn BXCLXXX. study sites I'd in cancer is neuroendocrine - Ib/Xa pembrolizumab label The for combination BXCLXXX in Keytruda multiple with patient like of to second enrollment. program,
to of Additionally, Marsden prominent more March, prostate figure also is the to us his advisory de Ib/Xa the expanding step working be and cancer toward we de the footprint a clinical in member our Bono the allow who major benefit are Professor board. our U.K. Phase to with global NHS with we principal for the Institute recently investigator as filing arena, authority, study which expertise Immuno-oncology clinical a took from the in the and will Professor trial the U.K. clinical application with approved, the Royal Bono study be late of of foundation will Cancer a European of to Research, Johann trust on joined a The broadly board. expand trial excited advisory him and our once
Nektar triple Administration treatment we to avelumab to BXCLXXX, are Merck, NKTR-XXX Drug we and the for pancreatic Pfizer IND Food proposed from combination Turning from cancer. and and the U.S. with on that filed study of pleased of the report
provide will provide under Pfizer reminder, NKTR-XXX. Merck a avelumab - the gauge Nektar and the agreement, As and will
ourselves costs with clinical the manage program between and initiate will equally shared development Nektar. and We
combination recent action. also trial begin focus study will mechanism of cancer. tumors. and combination both trial of pancreatic of clinical based in solid the preclinical for as we for development. its This achieved on study data from AACR the models Annual OXXX presented BXCLXXX on a I/O This have agent agonist trial further BXCLXXX's in in other and We anticancer At is the Meeting this this combination first two and a BXCLXXX with selected in possible of versatile potentially ability an mechanism increase expected sites validating therapy validating a in to half a year. as effective further in to to stimulate The potentially versus proof conduct We adaptive BXCLXXX plan significant April, certain immunity. combination to the innate control, tumor activity promising
seasoned others. other In among over medical as XX development designing commercialization veteran, with at and commercial medical Dr. strategy experience He Vice and and Commercial Pascal executing marketing we executive year management of achieve Dr. Borderies first Health responsible global ourselves appointment continue many science including affairs progresses. we highly and in team quarter Schering-Plough years' Consumer the the XXXX, with positioned and efforts. to Medical life strengthen companies President, as affairs the of significant a is to is Finally, and including our the sales for Borderies BTI's industry Affairs. milestones several Development Novartis reached
all We safety sharing study the data in those the and weeks. our from BXCLXXX are eagerly look to forward and coming with results of you awaiting results PK
Those in what be to advisory morning, this we on release in are a the neuroscience in noted Investor welcome from area our XX of should exciting be we board. the presentation York. Day for us May clinical BXCLXXX-focused As including several press members will event, hosting New an join
you're in (XXX) Ruth Acorda Group The at If of would [ph] attending please contact more interested like or details, John XXX-XXXX.
continued Richard And thank holds Therapeutics, of our for BioXcel the that, developing to mission the of you over CFO, and always, hope neuroscience medicines excitement I over share would With the I As your Richard? turn that you support like of our to the Immuno-oncology. call for future wave and across next company. what Steinhart.